We are live on ! Find out more
CARM

Carisma Therapeutics

Delisted

CARM was delisted on the 10th of October, 2025.

43 hedge funds and large institutions have $43.6M invested in Carisma Therapeutics in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,501% more call options, than puts

Call options by funds: $2.48M | Put options by funds: $155K

126% more capital invested

Capital invested by funds: $19.3M → $43.6M (+$24.3M)

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

50% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 8

0.23% more ownership

Funds ownership: 1.21%1.43% (+0.23%)

10% less funds holding

Funds holding: 4843 (-5)

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

Holders
43
Holders Change
-5
Holders Change %
-10.42%
% of All Funds
0.93%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
13
Increased
12
Reduced
8
Closed
18
Calls
$2.48M
Puts
$155K
Net Calls
+$2.33M
Net Calls Change
+$2.29M

CARM Hedge Fund Activity: Q2 2019 in Review

43 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2019, worth a combined $43.6M — up 126% from $19.3M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CARM and 13 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 12 added.

The largest buyer was CVI Holdings, opening a new position worth an estimated $12.1M. The largest seller was Castle Hook Partners, exiting entirely with an estimated $1.3M sold.

  • 43 institutional investors held Carisma Therapeutics (CARM) as of Q2 2019, down from 48 in Q1 2019.
  • Funds reported $43.6M of Carisma Therapeutics stock for Q2 2019, up 126% quarter-over-quarter.
  • 13 funds opened new Carisma Therapeutics positions in Q2 2019 and 18 closed out, a net change of -5 holders.
  • The largest Carisma Therapeutics buyer in Q2 2019 was CVI Holdings, an estimated $12.1M added.
  • The largest Carisma Therapeutics seller in Q2 2019 was Castle Hook Partners, an estimated $1.3M sold.

Based on aggregated 13F filings for Q2 2019.